目的 探討前列舒通膠囊聯(lián)合坦索羅辛治療IIIB型前列腺炎的臨床療效。方法 以2015年8月-2016年8月在南陽市中心醫(yī)院進行治療的88例ⅢB型前列腺炎患者為研究對象，根據(jù)治療方案的差別分為對照組和治療組，每組各44例。對照組口服鹽酸坦索羅辛緩釋膠囊，1粒/次，1次/d。治療組在對照組基礎(chǔ)上口服前列舒通膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療6周。觀察兩組的臨床療效，比較兩組NIH-CPSI評分、白細胞、最大尿流率的情況。結(jié)果 治療后，對照組、治療組總有效率分別為79.55%、95.45%，兩組總有效率比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組疼痛不適、排尿癥狀、生活質(zhì)量評分和NIH-CPSI評分總分均顯著降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組降低得更顯著，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組前列腺液中白細胞顯著降低，最大尿流率顯著升高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 前列舒通膠囊聯(lián)合鹽酸坦索羅辛緩釋膠囊治療IIIB型前列腺炎效果顯著，可明顯改善患者臨床癥狀，值得臨床推廣應(yīng)用。

Objective To investigate clinical curative effect of Qianlie Shutong Capsules combined with tamsulosin in treatment of non inflammatory prostatitis. Methods Patients (88 cases) with non inflammatory prostatitis in Nanyang City Center Hospital from August 2015 to August 2016 were randomly divided into control and treatment groups based on different treatments, and each group had 44 cases. Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 1 capsule/time, once daily. Patients in the treatment group were po administered with Qianlie Shutong Capsules on the basis of the control group, three capsules/time, three times daily. Patients in two groups were treated for 3 weeks. After treatment, the clinical efficacies were evaluated, and NIH-CPSI scores, WBC, and maximum urine flow rate in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.55% and 95.45%, respectively, and there were differences between two groups (P<0.05). After treatment, pain discomfort, voiding symptoms, quality of life, and total scores in NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, prostate fluid WBC in two groups were significantly decreased, but maximum urine flow rates in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Qianlie Shutong Capsules combined with Tamsulosin Hydrochloride Sustained Release Capsules has clinical curative effect in the treatment of non inflammatory prostatitis, can significantly improve the clinical symptoms, which has a certain clinical application value.